Low Skeletal Muscle as a Risk Factor for Worse Survival in Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus
- PMID: 37210313
- DOI: 10.1016/j.clgc.2023.04.005
Low Skeletal Muscle as a Risk Factor for Worse Survival in Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus
Abstract
Background: Renal cell carcinoma (RCC) with tumor thrombosis often requires nephrectomy and tumor thrombectomy. As an extensive and potentially morbid operation, patient preoperative functional reserve and body composition is an important consideration. Sarcopenia is a risk factor for increased postoperative complications, systemic therapy toxicity, and death solid organ tumors, including RCC. The influence of sarcopenia in RCC patients with tumor thrombus is not well defined. This study evaluates the prognostic ability of sarcopenia regarding surgical outcomes and complications in patients undergoing surgery for RCC with tumor thrombus.
Methods: We retrospectively analyzed patients with nonmetastatic RCC and tumor thrombus undergoing radical nephrectomy and tumor thrombectomy. Skeletal muscle index (SMI; cm2/m2) was measured on preoperative CT/MRI. Sarcopenia was defined using body mass index- and sex-stratified thresholds optimally fit via a receiver-operating characteristic analysis for survival. Associations between preoperative sarcopenia and overall (OS), cancer-specific survival (CSS), and 90-day major complications were determined using multivariable analysis.
Results: 115 patients were analyzed, with median (IQR) age and body mass index of 69 (56-72) and 28.6 kg/m2 (23.6-32.9), respectively. 96 (83.4%) of the cohort had ccRCC. Sarcopenia was associated with shorter median OS (P = .0017) and CSS (P = .0019) in Kaplan-Meier analysis. In multivariable analysis, preoperative sarcopenia was prognostic of shorter OS (HR = 3.38, 95% confidence interval [CI] 1.61-7.09) and CSS (HR = 5.15, 95% CI 1.46-18.18). Notably, 1 unit increases in SMI were associated with improved OS (HR = 0.97, 95% CI 0.94-0.999) but not CSS (HR = 0.95, 95% CI 0.90-1.01). No significant relationship between preoperative sarcopenia and 90-day major surgical complications was observed in this cohort (HR = 2.04, 95% CI 0.65-6.42).
Conclusion: Preoperative sarcopenia was associated with decreased OS and CSS in patients surgically managed for nonmetastatic RCC and VTT, however, was not predictive of 90-day major postoperative complications. Body composition analysis has prognostic utility for patients with nonmetastatic RCC and venous tumor thrombus undergoing surgery.
Keywords: Body composition; Inferior vena cava; Kidney cancer; Nephrectomy; Sarcopenia.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors of this manuscript have no conflicts of interest to disclose.
Similar articles
-
Prognostic Value of Sarcopenia and Albumin in the Surgical Management of Localized Renal Cell Carcinoma.Urol Oncol. 2023 Jan;41(1):50.e19-50.e26. doi: 10.1016/j.urolonc.2022.09.020. Epub 2022 Oct 21. Urol Oncol. 2023. PMID: 36280529
-
Impact of sarcopenia on post-operative outcomes following nephrectomy and tumor thrombectomy for renal cell carcinoma with inferior vena cava thrombus.Jpn J Clin Oncol. 2021 Apr 30;51(5):819-825. doi: 10.1093/jjco/hyaa275. Jpn J Clin Oncol. 2021. PMID: 33558883
-
Sarcopenia and modified Glasgow Prognostic Score predict postsurgical outcomes in localized renal cell carcinoma.Cancer. 2021 Jun 15;127(12):1974-1983. doi: 10.1002/cncr.33462. Epub 2021 Mar 24. Cancer. 2021. PMID: 33760232
-
Surgical Management of Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus.Urol Clin North Am. 2023 May;50(2):261-284. doi: 10.1016/j.ucl.2023.01.007. Urol Clin North Am. 2023. PMID: 36948671 Review.
-
The role of sarcopenia in treatment-related outcomes in patients with renal cell carcinoma: A systematic review and meta-analysis.Medicine (Baltimore). 2022 Oct 28;101(43):e31332. doi: 10.1097/MD.0000000000031332. Medicine (Baltimore). 2022. PMID: 36316941 Free PMC article.
Cited by
-
Creatinine to Cystatin-C Ratio in Renal Cell Carcinoma: A Clinically Pragmatic Prognostic Factor and Sarcopenia Biomarker.Oncologist. 2023 Dec 11;28(12):e1219-e1229. doi: 10.1093/oncolo/oyad218. Oncologist. 2023. PMID: 37540787 Free PMC article.
-
Muscle matters: Skeletal muscle index and body mass index impact on complications and survival in renal cancer.BJUI Compass. 2024 Jun 13;5(8):783-790. doi: 10.1002/bco2.405. eCollection 2024 Aug. BJUI Compass. 2024. PMID: 39157166 Free PMC article.
-
A Nomogram Including Sarcopenia for Predicting Progression-Free Survival in Patients with Localized Papillary Renal Cell Carcinoma: A Retrospective Cohort Study.Ann Surg Oncol. 2024 Sep;31(9):5815-5826. doi: 10.1245/s10434-024-15666-2. Epub 2024 Jul 1. Ann Surg Oncol. 2024. PMID: 38954088
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials